Free Trial

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.11 -0.01 (-8.33%)
As of 11:20 AM Eastern

OBD vs. REDX, FARN, ETX, HEMO, and POLB

Should you buy Oxford BioDynamics stock or one of its competitors? Oxford BioDynamics's main competitors and comparable companies include Redx Pharma (REDX), Faron Pharmaceuticals Oy (FARN), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), and Poolbeg Pharma (POLB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to Redx Pharma?

Oxford BioDynamics (LON:OBD) and Redx Pharma (LON:REDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Oxford BioDynamics had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Redx Pharma. Oxford BioDynamics' average media sentiment score of 0.32 beat Redx Pharma's score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company Overall Sentiment
Oxford BioDynamics Neutral
Redx Pharma Neutral

Redx Pharma has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M12.37-£103.52M-£0.20N/A
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A

11.7% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 53.2% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Redx Pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Redx Pharma's return on equity of -180.80% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Redx Pharma N/A -180.80%-43.95%

Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market.

Summary

Redx Pharma beats Oxford BioDynamics on 7 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Faron Pharmaceuticals Oy?

Oxford BioDynamics (LON:OBD) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Oxford BioDynamics and Oxford BioDynamics both had 1 articles in the media. Oxford BioDynamics' average media sentiment score of 0.32 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford BioDynamics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Faron Pharmaceuticals Oy
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

11.7% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 53.2% of Oxford BioDynamics shares are owned by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Faron Pharmaceuticals Oy has lower revenue, but higher earnings than Oxford BioDynamics. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M12.37-£103.52M-£0.20N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.116, meaning that its share price is 12% more volatile than the broader market.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

Summary

Oxford BioDynamics beats Faron Pharmaceuticals Oy on 7 of the 11 factors compared between the two stocks.

How does Oxford BioDynamics compare to e-therapeutics?

Oxford BioDynamics (LON:OBD) and e-therapeutics (LON:ETX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

e-therapeutics has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. e-therapeutics' return on equity of -38.75% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
e-therapeutics N/A -38.75%-29.10%

Oxford BioDynamics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

e-therapeutics has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M12.37-£103.52M-£0.20N/A
e-therapeutics£295K0.00-£10.06M-£0.02N/A

In the previous week, Oxford BioDynamics had 1 more articles in the media than e-therapeutics. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for e-therapeutics. Oxford BioDynamics' average media sentiment score of 0.32 beat e-therapeutics' score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company Overall Sentiment
Oxford BioDynamics Neutral
e-therapeutics Neutral

11.7% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 53.2% of Oxford BioDynamics shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

e-therapeutics beats Oxford BioDynamics on 8 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Hemogenyx Pharmaceuticals' return on equity of -409.57% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -409.57% -37.79%
Oxford BioDynamics -825.61%-451.74%-56.23%

Hemogenyx Pharmaceuticals has a beta of 1.487, meaning that its share price is 49% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are held by institutional investors. 0.9% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 53.2% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Oxford BioDynamics. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£130.80N/A
Oxford BioDynamics£1.20M12.37-£103.52M-£0.20N/A

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 2 mentions for Hemogenyx Pharmaceuticals and 1 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.32 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hemogenyx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oxford BioDynamics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Hemogenyx Pharmaceuticals and Oxford BioDynamics tied by winning 6 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Poolbeg Pharma?

Oxford BioDynamics (LON:OBD) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Poolbeg Pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Poolbeg Pharma's return on equity of -71.28% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Poolbeg Pharma N/A -71.28%-21.33%

In the previous week, Oxford BioDynamics had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Poolbeg Pharma. Oxford BioDynamics' average media sentiment score of 0.32 beat Poolbeg Pharma's score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company Overall Sentiment
Oxford BioDynamics Neutral
Poolbeg Pharma Neutral

Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.841, suggesting that its share price is 84% more volatile than the broader market.

Oxford BioDynamics has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M12.37-£103.52M-£0.20N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.79N/A

11.7% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 4.5% of Poolbeg Pharma shares are owned by institutional investors. 53.2% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Oxford BioDynamics beats Poolbeg Pharma on 8 of the 12 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

MetricOxford BioDynamicsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£14.79M£4.11B£7.88B£2.84B
Dividend YieldN/A3.64%2.47%5.11%
P/E Ratio-0.5524.5133.3323.37
Price / Sales12.3715.118.125.05
Price / Cash3.9821.8921.0220.23
Price / Book0.144.414.802.51
Net Income-£103.52M-£24.19M£3.52B£5.88B
7 Day PerformanceN/A-6.16%-4.56%-0.01%
1 Month Performance-7.56%-3.80%-2.78%-2.15%
1 Year Performance-61.13%-3.50%0.12%7.21%

Oxford BioDynamics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.11
-8.3%
N/A-57.6%£14.79M£1.20MN/A45
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
FARN
Faron Pharmaceuticals Oy
N/AGBX 28.30
-5.7%
N/A-84.7%£57.42MN/AN/A34
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 690.92
+10.7%
N/A-25.9%£47.65MN/AN/A14

Related Companies and Tools


This page (LON:OBD) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners